Brief: Haemonetics Corp Qtrly Revenue $331 Million
08/05/2025 12:29
May 8 (Reuters) - Haemonetics Corp HAE.N: QTRLY REVENUE $331 MILLION QTRLY ADJUSTED EARNINGS PER DILUTED SHARE $1.24 : ON TRACK TO DELIVER ALL OF THE GOALS OF OUR FOUR-YEAR LONG-RANGE PLAN IN FISCAL 2026 OUTLOOK FY26 ADJUSTED EARNINGS PER DILUTED SHARE $4.70 – $5.00 Q4 EARNINGS PER SHARE VIEW $1.22, REVENUE VIEW $329.4 MILLION -- LSEG IBES DATA FY2026 EARNINGS PER SHARE VIEW $4.93 -- LSEG IBES DATA Source text: ID:nPn2qZ6Q1a Further company coverage: HAE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Haemonetics
See all newsBrief: Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System
Haemonetics says FDA clears vascular closure device
US STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Haemonetics surges as CSL plans to move all US plasma centers to its devices